Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 May;46(5):840-9.

Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation

Affiliations

Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation

Yuni K Dewaraja et al. J Nucl Med. 2005 May.

Abstract

(131)I radionuclide therapy studies have not shown a strong relationship between tumor absorbed dose and response, possibly due to inaccuracies in activity quantification and dose estimation. The goal of this work was to establish the accuracy of (131)I activity quantification and absorbed dose estimation when patient-specific, 3-dimensional (3D) methods are used for SPECT reconstruction and for absorbed dose calculation.

Methods: Clinically realistic voxel-phantom simulations were used in the evaluation of activity quantification and dosimetry. SPECT reconstruction was performed using an ordered-subsets expectation maximization (OSEM) algorithm with compensation for scatter, attenuation, and 3D detector response. Based on the SPECT image and a patient-specific density map derived from CT, 3D dosimetry was performed using a newly implemented Monte Carlo code. Dosimetry was evaluated by comparing mean absorbed dose estimates calculated directly from the defined phantom activity map with those calculated from the SPECT image of the phantom. Finally, the 3D methods were applied to a radioimmunotherapy patient, and the mean tumor absorbed dose from the new calculation was compared with that from conventional dosimetry obtained from conjugate-view imaging.

Results: Overall, the accuracy of the SPECT-based absorbed dose estimates in the phantom was >12% for targets down to 16 mL and up to 35% for the smallest 7-mL tumor. To improve accuracy in the smallest tumor, more OSEM iterations may be needed. The relative SD from multiple realizations was <3% for all targets except for the smallest tumor. For the patient, the mean tumor absorbed dose estimate from the new Monte Carlo calculation was 7% higher than that from conventional dosimetry.

Conclusion: For target sizes down to 16 mL, highly accurate and precise dosimetry can be obtained with 3D methods for SPECT reconstruction and absorbed dose estimation. In the future, these methods can be applied to patients to potentially establish correlations between tumor regression and the absorbed dose statistics from 3D dosimetry.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Two typical slices of voxel phantom show superimposed tumors. (A) Defined activity map. (B) Defined density map. (C) SPECT image. (D) Absorbed dose-rate map.
FIGURE 2
FIGURE 2
Evaluation procedure.
FIGURE 3
FIGURE 3
Counts in target VOI plotted as function of iteration number for HE collimator (A) and UHE collimator (B).
FIGURE 4
FIGURE 4
One slice of RIT patient CT image, SPECT image, and corresponding dose-rate map.
FIGURE 5
FIGURE 5
Differential dose-volume histogram corresponding to tumor outlined in patient image of Figure 4.

References

    1. Press O, Early J, Appelbaum F, et al. Phase II trial of I-131 B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet. 1995;346:336–340. - PubMed
    1. Kaminski MS, Zasadny KR, Francis IR. Iodine-131-anti B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974–1981. - PubMed
    1. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ. Increased survival associated with radiolabeled lym-1 therapy for non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Cancer. 1997;80:2706–2711. - PubMed
    1. Kaminski MS, Tuck M, Estes J, et al. I-131 tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441–449. - PubMed
    1. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem cell support for the treatment of neuroblastoma. J Clin Oncol. 2002;20:2142–2149. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources